|
|
|
Volumn 12, Issue 64, 2011, Pages 213-228
|
|
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DRUG DERIVATIVE;
FINGOLIMOD;
IMMUNOLOGIC FACTOR;
PROPANEDIOL DERIVATIVE;
SPHINGOSINE;
SPHINGOSINE 1 PHOSPHATE RECEPTOR;
ANIMAL;
CHEMISTRY;
DRUG ANTAGONISM;
DRUG DEVELOPMENT;
HUMAN;
IMMUNOLOGY;
METABOLISM;
MULTIPLE SCLEROSIS;
ORAL DRUG ADMINISTRATION;
REVIEW;
ADMINISTRATION, ORAL;
ANIMALS;
DRUG DISCOVERY;
HUMANS;
IMMUNOLOGIC FACTORS;
MULTIPLE SCLEROSIS;
PROPYLENE GLYCOLS;
RECEPTORS, LYSOSPHINGOLIPID;
SPHINGOSINE;
|
|
EID: 84555197737
PISSN: None
EISSN: 19447930
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (164)
|
|
References (0)
|
